| 摘要 |
A hydrophilic matrix is disclosed which comprises: a) at least one polyac rylic acid derivative in preferred amounts of 0.5 - 40%, b) at least one cel lulose ether in preferred amounts of 30 - 90% and c) at least one disintegra nt in preferred amounts of 2 - 50%, with respect to the weight of the matrix . This matrix is used in combination with at least one pharmaceutically acce ptable active principle for manufacturing solid bioadhesive controlled relea se formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. The matrix is used in s olid formulations in amounts of about 5 - 60%, preferably 20-40%, and the ac tive principle in amounts of about 2- 70 %, preferably 5-50% with respect to the weight of the formulation. |
